Lorin Brody
Psychiatric/Mental Health · Crystal Lake, ILNPI 1992234306
Payments from drug & device makers
Across 102 payments — averaging $18.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$476
- Braeburn Inc.$329
- Alkermes, Inc.$178
- Otsuka America Pharmaceutical, Inc.$147
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$116
- Johnson & Johnson$110
- plus $494 from 12 others
What the payments were for
- Food & beverage$1,850100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 27 | $476 |
| Braeburn Inc. | 27 | $329 |
| Alkermes, Inc. | 9 | $178 |
| Otsuka America Pharmaceutical, Inc. | 6 | $147 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $116 |
| Johnson & Johnson | 5 | $110 |
| Vanda Pharmaceuticals Inc. | 4 | $101 |
| Orexo US, Inc. | 4 | $87 |
| Indivior Inc. | 3 | $63 |
| Teva Pharmaceuticals USA, Inc. | 2 | $42 |
| Supernus Pharmaceuticals, Inc. | 2 | $36 |
| Lundbeck LLC | 2 | $34 |
| E.r. Squibb & Sons, L.L.C. | 1 | $25 |
| Avanir Pharmaceuticals, Inc. | 1 | $24 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| Corium, LLC | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| USWM, LLC | 1 | $13 |
How this compares
$1,850 in reported general payments places this provider in the 75th percentile of 922 psychiatric/mental health providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 86 | $16,042 |
| Lamotrigine ErLamotrigine | 15 | $1,548 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 15 | $475 |
| Hydroxyzine Hcl | 26 | $432 |
| Trazodone Hcl | 22 | $361 |
| Sertraline Hcl | 20 | $70 |
| Clonazepam | 15 | $68 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Crystal Lake
- Erin PetrusicChicago$517K
- Maurice BrownleeChicago$162K
- Melissa VitaleChicago$151K
- Alan AmbergChicago$119K
- Jaime MendozaMaryville$111K
- Jennifer TheryMaryville$83K
- Carole Weddington HuntGranite City$67K
- Jessica WhelanBloomington$55K
- Lynn LochnerKankakee$41K
- Julie CarbrayChicago$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.